Development

A novel mathematical approach for fitting concentration-response curves is proposed that offers a more accurate estimation of potency data.

Companies need to consider and address formulation challenges to employ a successful reformulation strategy.

The Start-Up Market at CPHI Barcelona brings together 27 start-ups, innovators, and small enterprises from across the pharma landscape.

New medications show exciting outcomes for weight loss.

Increasing molecular diversity is creating a need for the reinvention of process development and control strategies.

Pharma companies set goals and adopt more sustainable alternatives.

Learning from early market failures, the biopharma industry has worked to improve the fate of antibody drug conjugates.

FDA has accepted Ashland’s Viatel bioresorbable mPEG-PDLLA pharmaceutical excipient into the FDA Novel Excipient Review Pilot Program.

Roquette has launched excipients PEARLITOL CR-H and PEARLITOL 200 GT.

AstraZeneca’s Imjudo (tremelimumab) was approved by FDA in combination with Imfinzi (durvalumab) for treating unresectable liver cancer.

Using a minimum valuable product and process approach would make it is possible to discipline and structure the development of biopharmaceuticals in the fastest way possible.

There are many benefits of employing a reformulation strategy, but companies must also overcome a variety of challenges too.

A simplified downstream process can save time and costs but requires enabling technologies.

FDA is highlighting how the Patient-Focused Drug Development program has encouraged active involvement of many patient groups in bringing their perspectives into the process of developing, testing, and approving new medicines.

A combination of eye imaging techniques and adaptive optics has revealed key details of choroideremia.

The dedicated solid-state research and development suite is designed to promote discovery of novel polymorph, salt, and cocrystal forms.

Roquette’s acquisition of Crest Cellulose is designed to reinforce its presence in India and other countries in Asia.

CytoReason has announced an expanded collaboration deal with Pfizer to deliver AI for drug discovery and development.

Novo Nordisk and Microsoft are collaborating to accelerate drug discovery and development using big data and artificial intelligence.

Ensysce Biosciences and Quotient Sciences are partnering to develop and test Ensysce’s novel opioid designed to prevent abuse and overdose.

Research into oncolytic viruses potentiated by stem cells shows promise for treating cancer.

Manufacturing and processing challenges surrounding mRNA can be overcome in order to realize the true potential of a technology 30 years in the making.

Using an orthogonal approach to lipid nanoparticle analysis can increase the odds of project success.

The growth of the biopharmaceuticals market is feeding back into economies and, in part, is driving the boom in life sciences and biotech ecosystems.

An early drug candidate screening strategy should incorporate clear targets to lessen late-stage failure.